Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-8186

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-8186). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tab Usp 100mg (C4b81f90 Bcd0 45d0 99ce 35ca998d473a 00)

Losartan Potassium Tab. USP 100 mg film-coated tablet label from Preferred Pharmaceuticals, Inc. The label states it is a generic for Cozaar and contains lines for package size, expiration date, lot and batch numbers, and instructions. Manufacturer listed as Solco Healthcare U.S., LLC, Cranbury, NJ. Storage and warning instructions are also included. The label includes bilingual dosage instruction sections in English and Spanish on a yellow background.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of Losartan Potassium, showing the arrangement of atoms including chlorine, hydroxyl, and potassium ion groups in the molecule.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with a primary endpoint over 66 study months between Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents study months and the y-axis shows the percentage of patients with the primary endpoint. The graph notes an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium versus Atenolol.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months between two treatments: Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows a lower stroke incidence in patients treated with Losartan Potassium, with an adjusted risk reduction of 25% (p=0.001). The x-axis represents study months and the y-axis the percentage of affected patients.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot chart comparing primary endpoint events and stroke rates between Losartan Potassium and Atenolol within demographic subgroups. The chart shows hazard ratios and 95% confidence intervals across categories including age, gender, race, ISH, diabetes, and history of cardiovascular disease. Symbols denote event rates and sample sizes for each subgroup.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo. The x-axis represents time in months (0 to 48), and the y-axis represents the percentage of patients with an event (0% to 60%). The graph shows two curves: a solid line for Losartan Potassium and a dotted line for placebo, with a noted risk reduction of 16.1% and a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.